Financial News · Live Terminal

Page 190 of 193

Mizuho Adjusts Price Target on Boston Scientific to $90 From $115, Maintains Outperform Rating

Boston Scientific (BSX) has an average rating of buy and mean price target of $98.71, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $62.46, Change: $+0.67, Percent Change: +1.08%

$BSX

Australia25d ago

Mizuho Adjusts Price Target on ResMed to $255 From $300, Maintains Outperform Rating

ResMed (RMD) has an average rating of overweight and mean price target of $305.30, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $228.56, Change: $-0.31, Percent Change: -0.14%

$RMD

Australia25d ago

BMO Capital Adjusts Price Target on Qnity Electronics to $146 From $142, Maintains Outperform Rating

Qnity Electronics, Inc. (Q) has an average rating of buy and mean price target of $140.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $133.94, Change: $+3.29, Percent Change: +2.52%

Australia25d ago

Mizuho Adjusts Price Target on Intuitive Surgical to $525 From $575, Maintains Neutral Rating

Intuitive Surgical (ISRG) has an average rating of overweight and mean price target of $602.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $453.27, Change: $+2.65, Percent Change: +0.59%

$ISRG

Australia25d ago

BMO Capital Adjusts Price Target on CMS Energy to $86 From $80, Maintains Outperform Rating

CMS Energy (CMS) has an average rating of overweight and mean price target of $81.58, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $78.60, Change: $-0.78, Percent Change: -0.98%

$CMS

Australia25d ago

BMO Capital Adjusts Price Target on Dow to $42 From $35, Maintains Market Perform Rating

Dow (DOW) has an average rating of overweight and mean price target of $39.35, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $40.02, Change: $+1.01, Percent Change: +2.59%

$DOW

Australia25d ago

Mizuho Adjusts Price Target on Edwards Lifesciences to $95 From $100, Maintains Outperform Rating

Edwards Lifesciences (EW) has an average rating of overweight and mean price target of $97.27, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $77.90, Change: $+0.03, Percent Change: +0.04%

$EW

Australia25d ago

BMO Capital Adjusts Price Target on ServiceNow to $120 From $170, Maintains Outperform Rating

ServiceNow (NOW) has an average rating of buy and mean price target of $179.15, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $87.53, Change: $+4.53, Percent Change: +5.46%

$NOW

Australia25d ago

Vir Biotechnology Doses First Expansion Cohort Patient in Phase 1 Metastatic Prostate Cancer Trial

Vir Biotechnology (VIR) said Monday it has dosed the first patient in one of three expansion cohorts in a phase 1 trial assessing safety, pharmacokinetics and efficacy of VIR-5500 in metastatic prostate cancer.The company said the monotherapy expansion cohort in late-line metastatic castration-resistant prostate cancer is the first to begin enrollment.Vir said it expects to dose the first patients in the dose-expansion cohorts to evaluate VIR-5500 combined with an androgen receptor pathway inhibitor in early-line metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer, in the coming months.The company said it expects to launch pivotal phase 3 trials in 2027.Shares of Vir Biotechnology were down 1% in Monday trading.Price: $9.40, Change: $-0.10, Percent Change: -1.05%

$VIR

Australia25d ago

Chemed Signs $450 Million Amended, Restated Credit Agreement

Chemed (CHE) said Monday it has signed an amended and restated agreement for its credit facility.The terms of the agreement comprise a $450 million five-year revolving credit facility including $100 million for letters of credit, the company said.The interest rate of the credit agreement has a floating rate that is generally the secured overnight financing rate, or SOFR, plus an additional tiered rate linked to the company's current leverage ratio, Chemed said.The credit agreement also has an expansion feature allowing the company to increase the revolving facility by an extra $250 million, it said.Price: $386.01, Change: $+0.17, Percent Change: +0.04%

$CHE

Australia25d ago

Labcorp Partners With Children's Hospital of Philadelphia on Pediatric Diagnostics

Labcorp (LH) said Monday it is collaborating with the Children's Hospital of Philadelphia to develop and expand access to pediatric diagnostic tests across the US.Financial terms were not provided.The company said the agreement will combine its laboratory network with the hospital's research and clinical capabilities to support development and broader availability of new tests in areas including oncology, metabolic conditions and autoimmune disorders.Labcorp also said the collaboration is expected to establish a joint pipeline to identify and advance pediatric diagnostics and make them available nationally through its testing infrastructure.Price: $261.71, Change: $+0.76, Percent Change: +0.29%

$LH

Australia25d ago

Supermicro Introduces Three New Edge AI Systems Powered by AMD Processors

Supermicro (SMCI) said Monday that it is introducing three new edge artificial intelligence systems that are powered by Advanced Micro Devices' (AMD) EPYC 4005 series processors.The new AI systems include a compact mini-1U box system, a short-depth 1U rackmount system, and a slim tower system aiming to accelerate AI inferencing and general-purpose workloads in space and power-constrained environments, Supermicro said.Shares of the company were down 3% in recent Monday trading.Price: $24.79, Change: $-0.48, Percent Change: -1.88%

$AMD$SMCI

Australia25d ago

Septerna Doses First Participants in Phase 1 Clinical Trial For Hypoparathyroidism Drug

Septerna (SEPN) said Monday that initial participants have been dosed in a phase 1 clinical study of its experimental oral hypoparathyroidism treatment, SEP-479.The placebo-controlled evaluation will enroll a maximum of 150 healthy adults to assess the safety and physical processing of the medication across single and multiple ascending doses, the company said.The company will also monitor changes in blood calcium levels and other biological markers, with results anticipated in late 2026 or early 2027, it said.Price: $23.40, Change: $+0.31, Percent Change: +1.34%

$SEPN

Australia25d ago

Mizuho Adjusts Price Target on Medtronic to $120 From $125, Maintains Outperform Rating

Medtronic (MDT) has an average rating of overweight and mean price target of $109.52, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $86.85, Change: $-0.32, Percent Change: -0.37%

$MDT

Australia25d ago

RTX Wins Contracts From Bell Textron for US Army Future Long-Range Assault Aircraft

RTX (RTX) said Monday it has won multiple contracts from Bell Textron, a Textron (TXT) company, to provide five critical systems for the U.S. Army's MV-75 Future Long Range Assault Aircraft.The company said the systems include main power generation, the interconnect drive system, the SmartProbe air data system, cockpit seating and the ice protection system.The work will be completed in Colorado, Illinois, Iowa, Minnesota, New York, Ohio and West Virginia, the company said.Price: $202.58, Change: $+1.02, Percent Change: +0.51%

$RTX$TXT

Australia25d ago

BMO Capital Adjusts Price Target on American Electric Power to $141 From $136, Maintains Market Perform Rating

American Electric Power (AEP) has an average rating of overweight and mean price target of $138.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $135.52, Change: $-0.78, Percent Change: -0.57%

$AEP

Australia25d ago

BMO Capital Adjusts Price Target on LyondellBasell Industries to $82 From $68, Maintains Market Perform Rating

LyondellBasell Industries NV (LYB) has an average rating of hold and mean price target of $72.56, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $75.93, Change: $+2.21, Percent Change: +2.99%

$LYB

Australia25d ago

Mizuho Adjusts Price Target on Aon to $394 From $397, Maintains Outperform Rating

Aon (AON) has an average rating of overweight and mean price target of $392.16, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $317.50, Change: $+4.93, Percent Change: +1.58%

$AON

Australia25d ago

Mizuho Adjusts Price Target on Brown & Brown to $84 From $85, Maintains Outperform Rating

Brown & Brown (BRO) has an average rating of hold and mean price target of $79.60, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $66.04, Change: $+0.96, Percent Change: +1.48%

$BRO

Australia25d ago

Mizuho Adjusts Price Target on Willis Towers Watson Public to $353 From $358, Maintains Outperform Rating

Willis Towers Watson Public Company (WTW) has an average rating of overweight and mean price target of $363.80, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $282.19, Change: $+2.05, Percent Change: +0.73%

$WTW

Showing 3781-3800 of 3847